16499-60-8

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLORO-5-FLUOROQUINAZOLINE is used as a key intermediate in the synthesis of various pharmaceutical drugs for its ability to contribute to the development of biologically active molecules.
Used in Chemical Industry:
In the chemical industry, 4-CHLORO-5-FLUOROQUINAZOLINE is used as a precursor in the production of complex organic compounds, leveraging its unique structural features to create novel chemical entities.
Used in Medicinal Chemistry Research:
4-CHLORO-5-FLUOROQUINAZOLINE is employed as a building block in medicinal chemistry for the design and development of new drug candidates, capitalizing on its potential to enhance the pharmacological properties of molecules.
Used in Antimicrobial Applications:
4-CHLORO-5-FLUOROQUINAZOLINE is studied for its potential antimicrobial properties, serving as a compound of interest in the development of new antimicrobial agents to combat resistant strains of bacteria.
Used in Antitumor Applications:
4-CHLORO-5-FLUOROQUINAZOLINE has been investigated for its antitumor properties, indicating its potential use in oncology for the development of novel therapeutics targeting various types of cancer.

Upstream product

• 436-72-6 5-fluoroquinazolin-4(3H)-one 
• 77326-36-4 2-amino-6-fluorobenzonitrile 
• 115643-59-9 2-amino-6-fluorobenzamide 

Downstream Products

• 524955-33-7 N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-fluoroquinazolin-4-amine 
• 786689-37-0 2-chloro-4-[(5-fluoroquinazolin-4-yl)amino]phenol 
• 786689-74-5 4-[(5-fluoroquinazolin-4-yl)amino]-2-methoxyphenol 
• 848482-94-0 5-fluoro-N-{3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}quinazolin-4-amine 
• 786689-78-9 2-fluoro-4-[(5-fluoroquinazolin-4-yl)amino]phenol 
• 744194-19-2 5-fluoro-N-[1-(3-fluorobenzyl)-1H-indazol-5-yl]quinazolin-4-amine 

Relevant academic research and scientific papers

POCl3 Chlorination of 4-Quinazolones

The reaction of quinazolones with POCl3 to form the corresponding chloroquinazolines occurs in two distinct stages, which can be separated through appropriate temperature control. An initial phosphorylation reaction occurs readily under basic conditions (R3N, aq pK a > 9) at t 3 addition. Clean turnover of phosphorylated quinazolones to the corresponding chloroquinazoline is then achieved by heating to 70-90 C. (N)- and (O)-phosphorylated intermediates, involving multiple substitution at phosphorus, have been identified and their reactions monitored using a combination of 1H, 31P, and 19F NMR. Kinetic analysis of the reaction profiles suggest that the various intermediates react with both Cl- and Cl2P(O)O-, but product formation arises exclusively from reaction of (O)-phosphorylated intermediates with Cl-. (O)- and (N)-phosphorylated intermediates equilibrate rapidly on the time scale of the reaction. A minimum of 1 molar equiv of POCl3 is required for efficient conversion of the intermediates to product.

Synthesis and biological evaluation of new tetramethylpyrazine-based chalcone derivatives as potential anti-Alzheimer agents

In the current study, a series of new ligustrazine-based chalcones was synthesized. For insertion of tetramethylpyrazine (TMP, also designated as ligustrazine) in chemical backbone of chalcone, a new ligustrazine-based aldehyde was prepared. New ketones were synthesized for inclusion of quinazolin-4-yl amino and pyrazin-2-yl amino moieties. The newly synthesized compounds were screened for acetylcholinesterase, butyrylcholinesterase, and monoamine oxidases (MAO) inhibitory activities and also for in vitro cytotoxicity on PC12 cells. The effect of these compounds against amyloid β-induced cytotoxicity and aggregation was also investigated. The synthesized compounds effectively inhibited the related enzymes and also exhibited neuroprotective effects. Most of the compounds displayed better inhibitory potencies against Aβ aggregation than reference compounds. Some compounds such as 11e and 16b showed very potent effects on multiple targets exhibiting behavior as multifunctional anti-Alzheimer agents.

ERBB RECEPTOR INHIBITORS

Disclosed are compounds inhibiting ErbBs (e. g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

4- (IH-INDAZOL-S-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER

A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blood

QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS

A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blood

CHEMICAL COMPOUNDS

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

INDAZOLYLAMINO QIONAZOLINE DERIVATIVES AS ANTITUMOR AGENTS

A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blo

INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS

A quinazoline derivative of the Formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.

QUINAZOLINE DERIVATIVES AS INHIBITORS OF EGF AND/OR ERBB2 RECEPTOR TYROSINE KINASE

A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.

QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS

A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.